Gradalis, a Carrollton, TX-based developer of drugs, vaccines, tools and diagnostics for the treatment of cancer, has closed on $24 million for its Series B round of financing. According to the company’s website, it has “two primary platforms, one centered on personalized autologous vaccines (FANG) and a second focused on bifunctional short hairpin RNA (shRNA) to enable specific protein knockdown.” Gradalis will reportedly use the funding to advance its platforms through late-stage clinical trials while expanding manufacturing capabilities and the commercial launch of its products.
